Back to Search
Start Over
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
- Source :
-
Frontiers in immunology [Front Immunol] 2020 Dec 15; Vol. 11, pp. 580328. Date of Electronic Publication: 2020 Dec 15 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- CAR T cell approaches to effectively target AML and T-ALL without off-tumor effects on healthy myeloid or T cell compartments respectively are an unmet medical need. NKG2D-ligands are a promising target given their absence on healthy cells and surface expression in a wide range of malignancies. NKG2D-ligand expression has been reported in a substantial group of patients with AML along with evidence for prognostic significance. However, reports regarding the prevalence and density of NKG2D-ligand expression in AML vary and detailed studies to define whether low level expression is sufficient to trigger NKG2D-ligand directed CART cell responses are lacking. NKG2D ligand expression in T-ALL has not previously been interrogated. Here we report that NKG2D-ligands are expressed in T-ALL cell lines and primary T-ALL. We confirm that NKG2D-ligands are frequently surface expressed in primary AML, albeit at relatively low levels. Utilizing CAR T cells incorporating the natural immune receptor NKG2D as the antigen binding domain, we demonstrate striking in vitro activity of CAR T cells targeting NKG2D-ligands against AML and T-ALL cell lines and show that even low-level ligand expression in primary AML targets results in robust NKG2D-CAR activity. We found that NKG2D-ligand expression can be selectively enhanced in low-expressing AML cell lines and primary AML blasts via pharmacologic HDAC inhibition. Such pharmacologic NKG2D-ligand induction results in enhanced NKG2D-CAR anti-leukemic activity without affecting healthy PBMC, thereby providing rationale for the combination of HDAC-inhibitors with NKG2D-CAR T cell therapy as a potential strategy to achieve clinical NKG2D-CAR T cell efficacy in AML.<br />Competing Interests: GD is currently an employee of Novartis and owns Novartis stock. JR reports research funding from Amgen, Equillium, and Kite Pharma, and consulting income from Avrobio, Falcon Therapeutics, Infinity Pharmaceuticals, LifeVault Bio, Rheos Medicines, Talaris Therapeutics and TScan Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2020 Driouk, Gicobi, Kamihara, Rutherford, Dranoff, Ritz and Baumeister.)
- Subjects :
- Cell Line, Tumor
Humans
Leukemia, Myeloid, Acute immunology
Ligands
NK Cell Lectin-Like Receptor Subfamily K metabolism
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma immunology
T-Lymphocytes transplantation
Treatment Outcome
Immunotherapy, Adoptive methods
Leukemia, Myeloid, Acute therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma therapy
Receptors, Chimeric Antigen metabolism
T-Lymphocytes physiology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33384686
- Full Text :
- https://doi.org/10.3389/fimmu.2020.580328